European Union research programme receives 7% boost:
This article was originally published in Clinica
Executive Summary
Funding of the European Union's Fourth Framework Research programme, which includes Ecu 888 million ($668 million) for biotechnology, biomedicine and health, is to receive a 7% top- up to Ecu 13,160 million due to the recent expansion of the Union to include Austria, Finland and Sweden. The increase was agreed at the European Parliament's July session in Strasbourg where another more contentious issue was debated concerning the level of additional funding to be allocated when the four-year programme is subjected to mid-term review in 1997.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.